Liana Dimitrakopoulou - Lavipharm Investor Officer
LAVI Stock | EUR 0.84 0.01 1.20% |
Insider
Liana Dimitrakopoulou is Investor Officer of Lavipharm SA
Phone | 30 210 66 91 000 |
Web | https://www.lavipharm.gr |
Lavipharm Management Efficiency
The company has return on total asset (ROA) of 0.0403 % which means that it generated a profit of $0.0403 on every $100 spent on assets. This is way below average. Lavipharm's management efficiency ratios could be used to measure how well Lavipharm manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Ioannis Aloukos | Aegean Airlines SA | N/A | |
Aristodimos Dimitriadis | Hellenic Telecommunications Org | 58 | |
Dr JD | Marfin Investment Group | 59 | |
Evrikos Sarsentis | Hellenic Telecommunications Org | N/A | |
Georgios Efstratiadis | Marfin Investment Group | N/A | |
Dimitris Karabetsos | Sidma SA Steel | 57 | |
Roland Jaggi | Aegean Airlines SA | N/A | |
John Veiopoulos | Sidma SA Steel | N/A | |
Dimitrios Gerogiannis | Aegean Airlines SA | N/A | |
Anastasios Kapenis | Hellenic Telecommunications Org | N/A | |
Styliani Dimaraki | Aegean Airlines SA | N/A | |
Andreas Tsangaris | Performance Technologies SA | N/A | |
Aristides Kamvysis | Aegean Airlines SA | N/A | |
Antonis Karadeloglou | Sidma SA Steel | N/A | |
Charalampos Mazarakis | Hellenic Telecommunications Org | 59 | |
Konstantinos Ploumpis | Hellenic Telecommunications Org | 55 | |
Eftichios Vassilakis | Aegean Airlines SA | 56 | |
Efstathia Presveia | Attica Bank SA | N/A | |
Stavroula Markouli | Marfin Investment Group | N/A | |
Georgios Triantafyllopoulos | Attica Bank SA | N/A | |
Eirini Nikolaidi | Hellenic Telecommunications Org | 54 |
Management Performance
Return On Asset | 0.0403 |
Lavipharm SA Leadership Team
Elected by the shareholders, the Lavipharm's board of directors comprises two types of representatives: Lavipharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lavipharm. The board's role is to monitor Lavipharm's management team and ensure that shareholders' interests are well served. Lavipharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lavipharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
Katerina Fragioudakis, Head Chairman | ||
Vassilis Baloumis, Group CFO | ||
Panagiotis Giannouleas, COO Mang | ||
Spyridon Fotinos, Chief Officer | ||
Liana Dimitrakopoulou, Investor Officer | ||
Lucia Tweezers, VP Board | ||
Panagiotis Pavlou, Group Director | ||
Eleana Nikolopoulou, Group Sec | ||
Telemaque Lavidas, Ex Director |
Lavipharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lavipharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | 0.0403 | |||
Profit Margin | 0.02 % | |||
Operating Margin | 0.08 % | |||
Current Valuation | 59.98 M | |||
Shares Outstanding | 18.29 M | |||
Shares Owned By Insiders | 67.47 % | |||
Price To Earning | 12.42 X | |||
Price To Sales | 0.17 X | |||
Revenue | 41.37 M | |||
Gross Profit | 15.89 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.